{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:38:28Z","timestamp":1759538308584,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,22]],"date-time":"2021-08-22T00:00:00Z","timestamp":1629590400000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.yrtph.2021.104968","type":"journal-article","created":{"date-parts":[[2021,5,29]],"date-time":"2021-05-29T10:57:15Z","timestamp":1622285835000},"page":"104968","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["What happened to quinacrine non-surgical female sterilization?"],"prefix":"10.1016","volume":"124","author":[{"given":"Stephen D.","family":"Mumford","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yrtph.2021.104968_bib1","series-title":"Proceedings of the Third International Seminar on Maternal and Perinatal Mortality, Pregnancy Termination and Sterilization","first-page":"370","article-title":"Chemical female sterilization using quinacrine pellets","author":"Bhatt","year":"1980"},{"key":"10.1016\/j.yrtph.2021.104968_bib2","series-title":"Female Transcervical Sterilization","first-page":"71","article-title":"Teratologic and mutagenic studies with intrauterine quinacrine hydrochloride","author":"Blake","year":"1983"},{"key":"10.1016\/j.yrtph.2021.104968_bib3","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.yrtph.2009.07.008","article-title":"A lifetime cancer bioassay of quinacrine administered into the uterine horns of female rats","volume":"56","author":"Cancel","year":"2010","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2021.104968_bib4","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/10915810600605773","article-title":"A one-year neonatal mouse carcinogenesis study of quinacrine hydrochloride","volume":"25","author":"Cancel","year":"2006","journal-title":"Int. J. Toxicol."},{"key":"10.1016\/j.yrtph.2021.104968_bib5","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0015-0282(16)46703-8","article-title":"Pharmacokinetic studies on quinacrine following intrauterine administration to cynomolgus monkeys","volume":"38","author":"Dubin","year":"1982","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.yrtph.2021.104968_bib6","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0015-0282(16)46704-X","article-title":"Effect of intrauterine and intravascular quinacrine administration on histopathology, blood chemistry, and hematology in Cynomolgus monkeys","volume":"38","author":"Dubin","year":"1982","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.yrtph.2021.104968_bib7","series-title":"Female Transcervical Sterilization","first-page":"60","article-title":"Pharmacology of quinacrine hydrochloride with emphasis on its use as a tubal occluding agent","author":"Dubin","year":"1983"},{"key":"10.1016\/j.yrtph.2021.104968_bib8","series-title":"External Review of USAID's Current and Future Role in Contraceptive Research and Development","first-page":"12","author":"Duncan","year":"2006"},{"key":"10.1016\/j.yrtph.2021.104968_bib9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1478-811X-9-13","article-title":"Beyond DNA binding \u2013 a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation and cancers","volume":"9","author":"Ehsanian","year":"2011","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.yrtph.2021.104968_bib10","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0015-0282(99)00537-3","article-title":"Comparative effects of quinacrine and erythromycin in adult female rats: a non-surgical sterilization study","volume":"73","author":"Fail","year":"2000","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.yrtph.2021.104968_bib11","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1006\/rtph.1997.1125","article-title":"Neonatal mouse assay for tumorigenicity: alternative to the chronic rodent bioassay","volume":"26","author":"Flammang","year":"1997","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2021.104968_bib12","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jri.2012.12.003","article-title":"Quinacrine-induced occlusive fibrosis in the human fallopian tube is due to a unique inflammatory response and modification of repair mechanisms","volume":"97","author":"Growe","year":"2013","journal-title":"J. Reprod. Immunol."},{"first-page":"1","year":"2019","series-title":"Unintended Pregnancy in the United States","key":"10.1016\/j.yrtph.2021.104968_bib13"},{"key":"10.1016\/j.yrtph.2021.104968_bib14","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.yrtph.2015.02.006","article-title":"A critical examination of the mode of action of quinacrine in the reproductive tract in a 2- year rat cancer bioassay and its implications for human clinical use","volume":"71","author":"Haseman","year":"2015","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2021.104968_bib15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0140-6736(93)92302-A","article-title":"31,781 cases of nonsurgical female sterilization with quinacrine pellets in Vietnam","volume":"342","author":"Hieu","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.yrtph.2021.104968_bib16","unstructured":"ICH Harmonized Tripartite Guideline. Guidance for Industry: S1C(R2) Dose Selection for Carcinogenicity Studies. Current Step 4 Version, Parent Guideline Dated 27 October 1994, (Addendum on a Limit Dose Dated 17 July 1997 and Incorporated in November 2005), Revised on 11 March 2008, This Guideline Has Been Developed by the Appropriate ICH Expert Working Group and Has Been Subject to Consultation by the Regulatory Parties, in Accordance with the ICH Process. At Step 4 of the Process, the Final Draft Is Recommended for Adoption to the Regulatory Bodies of the European Union, Japan, and USA."},{"key":"10.1016\/j.yrtph.2021.104968_bib17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.contraception.2004.03.005","article-title":"Transcervical polidocanol as a nonsurgical method of female sterilization: a pilot study","volume":"70","author":"Jensen","year":"2004","journal-title":"Contraception"},{"key":"10.1016\/j.yrtph.2021.104968_bib18","series-title":"Female Transcervical Sterilization","first-page":"138","article-title":"Quinacrine Hydrochloride: future research","author":"King","year":"1983"},{"key":"10.1016\/j.yrtph.2021.104968_bib19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0010-7824(96)00174-6","article-title":"Phase I prehysterectomy studies of the transcervical administration of quinacrine pellets","volume":"54","author":"Laufe","year":"1996","journal-title":"Contraception"},{"key":"10.1016\/j.yrtph.2021.104968_bib20","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/S0020-7292(03)90089-0","article-title":"An FDA Phase I clinical trial of quinacrine sterilization (QS)","volume":"83","author":"Lippes","year":"2003","journal-title":"Int. J. Gynecol. Obstet."},{"key":"10.1016\/j.yrtph.2021.104968_bib21","first-page":"S3","article-title":"Guest editor, supplement: quinacrine sterilization: reports on 40,252 cases","volume":"83","author":"Lippes","year":"2003","journal-title":"Int. J. Gynecol. Obstet."},{"issue":"Suppl. l","key":"10.1016\/j.yrtph.2021.104968_bib22","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1080\/019262301753178537","article-title":"Neonatal mouse model: review of methods and results","volume":"29","author":"McClain","year":"2001","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.yrtph.2021.104968_bib23","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.yrtph.2009.12.007","article-title":"An alternative interpretation of, \u201cA lifetime cancer bioassay of quinacrine administered into the uterine horns of female rats","volume":"56","author":"McConnell","year":"2010","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2021.104968_bib24","first-page":"47","article-title":"Clinicopathologic study of fallopian tube closure after single transcervical insertion of quinacrine pellets","volume":"40","author":"Merchant","year":"1995","journal-title":"Int. J. Fertil."},{"year":"2012","series-title":"Intended and Unintended Births in the United States: 1982-2010","author":"Mosher","key":"10.1016\/j.yrtph.2021.104968_bib25"},{"key":"10.1016\/j.yrtph.2021.104968_bib26","series-title":"Female Transcervical Sterilization","first-page":"89","article-title":"Histologic changes following intrauterine administration of quinacrine hydrochloride","author":"Parmley","year":"1983"},{"year":"2002","series-title":"Chapter IV. B. 1. General Guidelines for Designing and Conducting Toxicity Studies","author":"Redbook","key":"10.1016\/j.yrtph.2021.104968_bib27"},{"issue":"76","key":"10.1016\/j.yrtph.2021.104968_bib28","first-page":"173","article-title":"FHI's decision to halt development of quinacrine: why and how","volume":"P48","author":"Sokal","year":"2007","journal-title":"Abstracts\/Contraception"},{"key":"10.1016\/j.yrtph.2021.104968_bib29","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0010-7824(84)90100-8","article-title":"Lack of tubal occlusion by intrauterine quinacrine and tetracycline in the primate","volume":"30","author":"Zaneveld","year":"1984","journal-title":"Contraception"},{"issue":"Suppl. 2","key":"10.1016\/j.yrtph.2021.104968_bib30","first-page":"S7","article-title":"Quinacrine sterilization: a retrospective","volume":"83","author":"Zipper","year":"2003","journal-title":"Int. J. Gynecol. Obstet."},{"key":"10.1016\/j.yrtph.2021.104968_bib31","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/j.1879-3479.1980.tb00496.x","article-title":"Quinacrine hydrochloride pellets: preliminary data on a nonsurgical method of female sterilization","volume":"18","author":"Zipper","year":"1980","journal-title":"Int. J. Gynecol. Obstet."}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230021001082?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230021001082?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:31:44Z","timestamp":1759494704000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230021001082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":31,"alternative-id":["S0273230021001082"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2021.104968","relation":{},"ISSN":["0273-2300"],"issn-type":[{"type":"print","value":"0273-2300"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What happened to quinacrine non-surgical female sterilization?","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2021.104968","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"104968"}}